A naukri.com initiative
TechCrunch
1M
243
Image Credit: TechCrunch
MiLaboratories gets $10M for a platform play to accelerate genomic research
- MiLaboratories has raised $10m in a recent series A funding round led by Spanish investment company Kfund. The company has spent the last four years developing a computational biology platform to help scientists, particularly bioinformaticians, process, analyse and aggregate genomic data. Its SDK, Platforma.bio, has been in beta testing, with about 300 labs using it and 20 apps so far developed. The platform aims to free up bioinformaticians who spend much of their time processing NGS data to focus on more complex tasks with greater potential for cutting-edge science. Many big pharma companies, including Moderna, are already customers.
- MiLaboratories’ platform is aimed at scientists whose skillsets span biology, computer science and maths, and incorporates features such as data visualisation and generative AI, as well as a marketplace for other researchers to distribute more specialised computation tools in the form of apps. Most bioinformatics tools are either commercially focused or have been developed within academia, where utility tends to be prioritised over usability. MiLaboratories hopes its platform will offer both.
- MiLaboratories’ platform is designed to be a marketplace for other scientists who want to distribute more specialised computation tools in the form of apps to the genomic research community. Its platform is built around data visualisation and generative AI, and is designed to help scientists process, analyse and aggregate genomic data. The platform is also designed to make it easier for bioinformaticians to use their skills to build algorithms that might help advance cutting-edge science. MiLaboratories’ Series A is led by Madrid-based Kfund, with participation from Acrobator Ventures, EGB Capital, Courtyard Ventures, Somersault Ventures, Speedinvest and Ten13.
- MiLaboratories’ computational biology platform is designed to help bioinformaticians more easily process, analyse and aggregate genomic data. The platform will also offer a marketplace for other scientists to distribute more specialised computation tools in the form of apps to expand its use. MiLaboratories hopes that in freeing bioinformaticians from processing NGS data, they can use their skills to advance cutting-edge science through the development of more complex tasks, such as building algorithms.
- MiLaboratories, a San Francisco-based start-up, has raised $10m through a recent series A funding round led by Kfund. The start-up has spent the last four years developing a computational biology platform, which aims to make it easier for bioinformaticians to process, analyse and aggregate big data from NGS technology. It employs data visualisation and generative AI technology. The platform is also designed to make it easier for bioinformaticians to create useful algorithms in order to advance cutting-edge science. MiLaboratories' financing round will be used to further develop the platform and build a community of app developers.
- San Francisco-based computational biology start-up MiLaboratories has raised $10m in a funding round to develop and expand its platform, which is designed to provide a marketplace for start-ups to build software to analyse and aggregate genetic data. Its prominent features include data visualisation tools and generative AI. The start-up's SDK – named Platforma.bio – has been in alpha and beta testing for the past few years, with an estimated 20 apps now made available through the platform. Some 300 labs have been using the SDK in this testing phase. MiLaboratories aims to make it easier for bioinformaticians and other scientists to process, analyse and aggregate genetic data.
- San Francisco-based start-up MiLaboratories has raised $10m in Series A funding to expand its computational biology platform, which has been in development since 2017. The platform uses data visualisation, AI and other technologies to enable scientists to process and analyse genetic data. The software also provides a marketplace for bioinformaticians and other scientists to distribute apps designed for specialised computation. This will free bioinformaticians from the day-to-day tasks of processing big data, allowing them to focus on developing more complex algorithms.
- San Francisco-based start-up MiLaboratories has raised $10m in funding to advance its computational biology platform, aimed at bioinformaticians and enabling them to process, analyse and aggregate big data from next-generation sequencing. The start-up offers a marketplace for other scientists to distribute their own specialised computation tools as apps. MiLaboratories has spent the past four years developing its software, which also incorporates data visualisation and generative AI.
- SF-based MiLaboratories has raised $10m in a KFund-led series A funding to expand its computational biology platform, designed to help bioinformaticians process, analyse and aggregate big data from next-generation sequencing more easily. The platform incorporates data visualisation and generative AI, as well as a marketplace for researchers to distribute specialised computation tools as apps. The start-up plans to continue developing the platform and build a community of app developers.
- San Francisco-based start-up, MiLaboratories has raised $10m in a recent series A funding round aimed at expanding a computational biology platform for bioinformaticians to process, analyse and aggregate massive amounts of genomic data. The firm's platform is built around data visualisation and generative AI to support usability and provides a marketplace for scientists to distribute their specialised computation tools as apps. The funding will be used to hire engineers and develop the platform's technology.
- San Francisco-based start-up, Milaboratories, will use a $10m won in a recent funding round to hone its computational biology platform, designed to help scientists with bioscience expertise to process vast amounts of genomic data, including visualisation and generative AI chalked up from next-generation sequencing (NGS) technology. As well as making data more accessible to bioinformaticians, it's hoped the platform will be an avenue for scientists to integrate and aggregate results from numerous analyses into a unified picture for more complex disease or cancer therapies.
Read Full Article
14 Likes
For uninterrupted reading, download the app